Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Inflammation × dolutegravir × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Opportunistic Infections 1 Inflammation 1 Epstein-Barr Virus Infections 1 Cytomegalovirus Infections 1 Coinfection 1 Acquired Immunodeficiency Syndrome 1

Interventions

dolutegravir 1 XENP 1595 1 Trimethoprim, Sulfamethoxazole Drug Combination 1 Ritonavir 1 Nucleosides 1 Darunavir 1 Clindamycin 1 Cephalexin 1 Anti-Bacterial Agents 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04183738 2020-11-10

i2-D²EFT

Kirby Institute

Phase 4 Withdrawn

Acquired Immunodeficiency Syndrome, Cytomegalovirus Infections, Inflammation, Opportunistic Infections, Epstein-Barr Virus Infections, Coinfection

Data powered by HemOnc (CC BY 4.0) Colophon ⚡